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Abstract: Manuka honey (MH) is used as an antibacterial agent in bioactive wound dressings via
direct impregnation onto a suitable substrate. MH provides unique antibacterial activity when
compared with conventional honeys, owing partly to one of its constituents, methylglyoxal (MGO).
Aiming to investigate an antibiotic-free antimicrobial strategy, we studied the antibacterial activity
of both MH and MGO (at equivalent MGO concentrations) when applied as a physical coating to
a nonwoven fabric wound dressing. When physically coated on to a cellulosic hydroentangled
nonwoven fabric, it was found that concentrations of 0.0054 mg cm−2 of MGO in the form of MH and
MGO were sufficient to achieve a 100 colony forming unit % bacteria reduction against gram-positive
Staphylococcus aureus and gram-negative Klebsiella pneumoniae, based on BS EN ISO 20743:2007.
A 3- to 20-fold increase in MGO concentration (0.0170–0.1 mg cm−2) was required to facilitate a
good antibacterial effect (based on BS EN ISO 20645:2004) in terms of zone of inhibition and lack of
growth under the sample. The minimum inhibitory concentration (MIC) and minimum bactericidal
concentration (MBC) was also assessed for MGO in liquid form against three prevalent wound and
healthcare-associated pathogens, i.e., Staphylococcus aureus, gram-negative Pseudomonas aeruginosa
and gram-positive Enterococcus faecalis. Other than the case of MGO-containing fabrics, solutions
with much higher MGO concentrations (128 mg L−1–1024 mg L−1) were required to provide either
a bacteriostatic or bactericidal effect. The results presented in this study therefore demonstrate
the relevance of an MGO-based coating as an environmentally friendly strategy for the design of
functional dressings with antibiotic-free antimicrobial chemistries.
Keywords: Manuka honey; methylglyoxal; nonwoven; antibacterial; wound dressing
1. Introduction
With an increasing bacterial resistance to antibiotics [1–3] and a concern to find alternative
treatments [3,4], the antibacterial activity of Manuka Honey (MH) is of growing interest and is well
documented. MH inhibits the growth of clinically-relevant pathogens and biofilms found in wounds,
including gram-positive strains such as Methicillin-resistant Staphylococcus aureus (MRSA) [5,6], and
Streptococcus pyogenes [7], and gram-negative strains including Esherichia coli [8], Proteus mirabilis and
Enterobacter cloacae [9], and P. aeruginosa [10,11]. Gastrointestinal pathogens [12] and oral infections [13]
have also shown susceptibility to MH. The effect of MH on cells required for healing, including
fibroblasts and keratinocytes also suggests that MH is considered a safe compound for topical
treatment [14,15]. Methylglyoxal (MGO) is a keto-aldehye found as a yellow liquid, and is present
in a variety of beverages and foods including wine, beer [16], bread [17], soya, coffee, teas [18]
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and notably, MH [19]. Mavric et al. [20] reported that MGO is responsible for the heightened
and unique non-peroxide antibacterial activity associated with MH, and the minimum inhibitory
concentrations (MIC) of MGO in the form of both MH and isolated synthetic compound required
to have an antibacterial effect have been established. For MGO, a MIC of 1.1 mM is required to
induce an antibacterial effect, whilst a range of MIC values has been observed in the case of MH,
in light of inherent variations in MGO content. For example, five MHs with MGO concentrations
ranging between 347 to 761 ± 25 mg kg−1 were shown to exhibit an antibacterial effect when the
MH was diluted to 15 to 30% (w/v). These resulting MGO concentrations correspond to MIC values
between 1.1 mM and 1.8 mM, and therefore compare with the 1.1 mM MIC value associated with
synthetic MGO [20]. The antibacterial activity of MGO in the form of solution [20,21], hydrogel [21],
polymer-based formulation [22], and poly (vinyl alcohol) fibres [23] has also been studied. With respect
to MH, MGO has attracted attention because of its ability to act as a lone compound at defined
concentration for the inhibition of bacterial growth, as well as its carcinostatic properties [24–28] and
anti-proliferative effects on leukaemia cells [29,30].
The antibacterial effects of MH and MGO in the form of nonwoven fabric coating have not
previously been compared in terms of concentration per unit area. This is particularly important when
designing dressings, where the required concentration of the active compound per unit area should be
known. Nonwovens in this context relate to textile materials produced by drylaid methods, which are
most commonly employed to manufacture wound dressings [20,31,32].
Therefore it is of interest to understand the degree to which MGO exhibits an equivalent
antibacterial effect to MH, aiming to identify a synthetically-defined alternative to MH towards
the design of antibacterial dressings. Consequently, the aim of this work was firstly to compare
and evaluate the antibacterial efficiency of both MH and MGO when applied as a coating to
a nonwoven fabric at equivalent MGO concentrations. Secondly, we wanted to determine the
minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of MGO
(isolated synthetic compound) in liquid form against three of the most common wound pathogens
including Staphylococcus aureus (S. aureus), Peudomonas aeruginosa (P. aeruginosa) and Enterococcus faecalis
(E. faecalis) [33].
2. Results and Discussion
The sample nomenclature used in this study is as follows: samples are coded as ‘MH1, MH2,
MGO1 and MGO2’, whereby ‘MH or MGO’ identifies the additive that the nonwoven samples were
prepared with, i.e., MH or MGO; and ‘1 or 2’ describes the concentration formulation as reported in
Table 1. ‘NW’ and ‘WP’ indicate the coating-free nonwoven and woven polyester control samples,
respectively. Table 1 provides an overview of the different sample additive formulations.
Table 1. MGO concentration in either the coating solutions (Cs) or resulting coated nonwoven
fabrics (Cf).
Sample ID Cs (mg g−1) Cf (mg cm−2)
MH1 0.11 0.0057
MH2 0.33 0.0169
MGO1 0.11 0.0054
MGO2 0.33 0.0170
2.1. Antibacterial Performance of the Nonwoven Coated Samples
2.1.1. Antibacterial Performance of the Nonwoven Coated Samples Using BS EN ISO 20743:2007
With reference to BS EN ISO 20743:2007 [34], the results in Tables 2 and 3 report the average
reduction of bacteria in colony forming units (CFU), for either S. aureus or Klebsiella pneumoniae
(K. pneumoniae), respectively. For the MH coated and synthetic MGO-coated nonwovens, a 100 CFU%
Materials 2017, 10, 954 3 of 14
reduction in bacteria was achieved for all samples where the calculated concentration of MGO ranged
from 0.0054 mg cm−2 to 0.0170 mg cm−2 regardless of the strain tested. Interestingly, an average
reduction of 97 CFU% in bacteria was still reported for the nonwoven control against S. aureus (Table 2),
whilst considerably high growth (−252 CFU%) was reported when the same sample was challenged
with K. pneumonia (Table 3). This latter effect was still observed in the case of the woven polyester
control following contact with either S. aureus or K. pneumoniae (−22,438 CFU% and −5635 CFU%).
Table 2. Average reduction in colony forming units (CFU) for S. aureus. Negative values indicate
bacteria growth.
Sample ID Average CFU Immediatelyafter Inoculation
Average CFU after 18
h in Incubation
Average Percentage
Reduction (CFU%)
NW 2.64 × 104 8.60 × 102 97
WP 1.30 × 105 2.93 × 107 −22,438
MH1 3.15 × 104 0 100
MH2 3.90 × 104 0 100
MGO1 3.20 × 104 0 100
MGO2 3.05 × 104 0 100
Table 3. Average reduction in colony forming units (CFU) for K. pneumoniae. Negative values indicate
bacteria growth.
Sample ID Average CFU Immediatelyafter Inoculation
Average CFU after 18
h in Incubation
Average Percentage
Reduction (CFU%)
NW 8.53 × 104 2.40 × 105 −252
WP 6.80 × 104 3.90 × 106 −5635
MH1 7.07 × 104 0 100
MH2 8.60 × 104 0 100
MGO1 7.20 × 104 0 100
MGO2 9.93 × 104 0 100
Previously, it has been reported that TENCEL® or lyocell fibres are able to reduce the growth of
S. aureus considerably when compared with synthetic fibres such as polypropylene, polyester and
polyacrylate [35]. The previous study showed that the synthetic samples exhibited 100 to 1000 times
higher bacteria growth when compared with lyocell. It is conceivable that the reduced growth of
bacteria observed with lyocell fibres is associated with the behaviour of the fibres in water. In the case
of the synthetic fibres, there is limited penetration of water into the fibres and interactions are mainly
at the surface which is fully accessible to bacterial organisms. However, because of the nanofibrillar
structure of lyocell fibres, water can be absorbed into the micro capillaries inside the fibre, such
that there is a reduced life sustaining environment for the bacteria to thrive [35]. It was reported
that approximately 1,333,000 nanofibrils with a diameter of 10 nm are apparent in a single TENCEL
fibre, thus contributing to the highly absorbent characteristic nature of the fibre [36]. This behaviour
is therefore a likely explanation as to why a reduced bacterial count (97 CFU%) was observed for
the NW control in the case of S. aureus in the present study. Following these considerations, the
thinner peptidoglycan and additional lipopolysaccharide layer present in gram-negative K. pneumoniae
compared to gram-positive S. aureus [37] are likely to provide K. pneumoniae with increased adaptability
on hydrated fibres in the experimental conditions investigated, explaining why K. pneumoniae growth,
rather than reduction, was observed in contact with the nonwoven, similarly to the polyester, control
(Table 3).
2.1.2. Antibacterial Performance of the Coated Nonwoven Samples Using BS EN ISO 20645:2004
Tables 4 and 5 summarise the results for the NW control and MH- and MGO-coated nonwoven
samples against E. coli and S. aureus respectively in accordance with BS EN ISO 20645:2004 [38].
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Figure 1 illustrates the influence of the NW control samples on the growth of bacteria. Figures 2 and 3
exemplify the effects that the MH- and MGO-coated samples have on the bacterial growth at varying
MGO concentrations.
Table 4. Effect of MGO concentration on the growth of E. coli when applied as a physical coating onto
nonwoven samples.
MH Coatings MGO Coatings
MGO
Concentration
(mg cm−2)
Inhibition
Zone (mm)
Growth under
Sample Assessment
Inhibition
Zone (mm)
Growth
under
Sample
Assessment
NW 0 Heavy Insufficient 0 Complete Insufficient
0.0054 0 Heavy Insufficient 0 Moderate Insufficient
0.0170 0 Slight Limited efficiency 0 No growth Good effect
0.10 0–1 No growth Good effect 0 No growth Good effect
0.15 0–1 No growth Good effect 0 No growth Good effect
0.20 >1 No growth Good effect 0 No growth Good effect
0.40 n/a * n/a n/a 0–1 No growth Good effect
0.80 n/a * n/a n/a >1 No growth Good effect
1.20 n/a * n/a n/a >1 No growth Good effect
* Owing to the viscosity of MH, it was not possible to prepare samples at concentrations above 0.2 mg cm−2.
Table 5. Effect of MGO concentration on the growth of S. aureus when applied as a physical coating
onto nonwoven samples.
MH Coatings MGO Coatings
MGO
Concentration
(mg cm−2)
Inhibition
Zone (mm)
Growth under
Sample Assessment
Inhibition
Zone (mm)
Growth
under
Sample
Assessment
NW 0 Heavy Insufficient 0 Heavy Insufficient
0.0054 0 Heavy Insufficient 0 Moderate Insufficient
0.0170 0 Heavy Insufficient 0 Slight Limit of efficiency
0.10 0–1 No growth Good effect 0 No growth Good effect
0.15 >1 No growth Good effect 0 No growth Good effect
0.20 >1 No growth Good effect 0 No growth Good effect
0.40 n/a * n/a n/a 0 No growth Good effect
0.80 n/a * n/a n/a >1 No growth Good effect
1.20 n/a * n/a n/a >1 No growth Good effect
* Owing to the viscosity of MH, it was not possible to prepare samples at concentrations above 0.2 mg cm−2.
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Figure 1. Effect of control samples on the growth of E. coli during (A,C) and following (B,D) incubation;
A = no inhibition zone; B = heavy growth under sample and S. aureus; C = no inhibition zone and
D = heavy growth under sample. Note: all samples were 3 cm in diameter.
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As shown in Figure 1A,C, no zone of inhibition was apparent with the control samples when
tested against both gram-negative E. coli and gram-positive S. aureus. Upon the removal of the control
samples from the surface of the agar, the contact zone between the sample and the agar presented
heavy bacterial growth (Figure 1B,D). This confirms that the control samples did not exhibit any
antibacterial activity. Whilst these observations appear to be in contrast with the results provided
in Table 2, it is important to note that in this case, the samples were directly tested in contact with
inoculated agar gels in the absence of simulated wound exudate solution (in contrast to the case of
the assay results provided in Table 2). Here, the bacteria-detrimental fibre-induced water uptake
effect was largely marginal, so that high growth of S. aureus was consequently still observed following
application of the nonwoven control sample. The antibacterial effect of the MH and MGO coatings
having equivalent MGO concentrations between 0.0054 mg cm−2 and 0.0170 mg cm−2 showed no
zone of inhibition for E. coli and S. aureus. Upon the removal of the MH coated samples from the agar,
heavy growth was apparent at an MGO concentration of 0.0054 mg cm−2 for both E. coli and S. aureus
(Figure 2A displays an example of heavy growth). Moderate growth was achieved for both E. coli and
S. aureus, upon the removal of the MGO-coated nonwovens at equivalent concentrations (an example
of moderate growth is shown in Figure 2B). At an MGO concentration of 0.0170 mg cm−2, moderate
and heavy growth was observed for E. coli and S. aureus respectively for the MH-coated samples.
However, for the MGO coatings with an equivalent MGO concentration of 0.0170 mg cm−2, no growth
and slight growth was evident against E. coli and S. aureus, respectively (examples of slight growth and
no growth are shown in Figure 2C,D). These initial evaluations at a concentration of 0.0054 mg cm−2
suggest that an insufficient antibacterial effect was achieved for both MH and MGO coatings. At a
concentration of 0.0170 mg cm−2, limited efficacy was observed for the MH coatings. However, for the
MGO coatings with an MGO concentration of 0.0170 mg cm−2, the antibacterial effect was shown to
improve slightly and a good antibacterial effect and a limit of efficiency was achieved for both E. coli
and S. aureus respectively.
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Fig re 2. Examples of bacteria growth under either MH- or GO-coated nonwoven samples. A = heavy
growth of E. coli; B = medium growth of S. Au eus; C = slight growth of S. aureus and D = no g owth of
E. coli. Note: all coated samples were 3 cm in diamet .
It is important to note that where no growth or inhibition zone was apparent, a good antibacterial
effect may still be observed. This may be linked to the diffusion rate of the active compound from the
fabric [38] to the agar plate and the affinity of the fibres for moisture. Thus, it is likely that, within
the time frames investigated in this study, the hygroscopic, crystalline nanofibrils of the TENCEL®
fibres [35] retain the MGO and honey coating, thereby limiting the diffusion of MGO into the agar at
these MGO concentrations. This situation may well be expected in this case, given that no additional
simulated wound exudate solution was applied. The minimal swelling of the fibres expected following
contact with the agar plate may well be directly related to a decreased MGO diffusion. This hypothesis
is supported when comparing data obtained in exudate-free conditions with the ones presented in
Tables 2 and 3, where complete bacteria killing was observed with the same MGO concentrations
following the addition of simulated wound exudate solution. As the MGO concentration increases to
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between 0.1 mg cm−2 and 1.2 mg cm−2, a good antibacterial effect is observed with both MH and MGO
in all cases (Tables 4 and 5). For the MH coated samples, mean zones of inhibition of 0–1 mm were
apparent against both E. coli and S. aureus at concentrations between 0.1 mg cm−2 and 0.2 mg cm−2.
Figure 3B displays an example of an inhibition zone from 0–1 mm. As the concentration of MGO
doubled to 0.2 mg cm−2, the mean zone of inhibition for E. coli and S. aureus increased to achieve a
mean zone of >1 mm. An example of a mean zone of >1 mm can be seen in Figure 3C.
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Conversely, the MGO coatings did not show a clear zone of inhibition until a concentration of
0.4 mg cm−2 was reached for E. coli and 0.8 mg cm−2 for S. aureus. Below these concentrations, no
evidence of bacterial growth was observed upon the removal of the samples, resulting in a good
antibacterial effect. However, a partial zone of inhibition was formed around the samples, as presented
in Figure 3D, suggesting that the TENCEL® fibres still retained a proportion of the MGO. As the
addition of MGO solution increased, the TENCEL® fibres uptake of, and ability to retain, the MGO
was reduced. This is expected to encourage greater diffusion of MGO into the bacteria-seeded agar,
resulting in a clear zone of inhibition. Figure 4 shows FEGSEM images of the dry (Figure 4A),
MGO-coated (Figure 4B) and the MH-coated (Figure 4C,D) TENCEL® fibres. It is apparent that the
MGO-coated TENCEL® fibres (Figure 4B) have a similar appearance to the dry TENCEL® fibres as
seen in Figure 4A, confirming that the liquid phase coating has been absorbed and retained by the
fibres. The MH-coated TENCEL® fibres appear mainly occluded by the honey coating (Figure 4C,D),
and some protruding fibres exhibit a globular surface coating due to the MH. These images provided
further evidence that the MH is freely available on the surface of the TENCEL® fibres, such that direct
contact with the bacteria agar can be anticipated. It is also likely that during incubation at 37 ◦C,
the MH coating will soften and allow greater diffusion into the bacteria-seeded agar from the fibres.
Previous studies have reported that temperature has a direct influence on the viscosity of honey [39–41]
such that as the temperature increases the viscosity falls due to reduced hydrodynamic forces and
reduced molecular interaction [41]. The viscosity measurements of the MH obtained during this study
confirmed this temperature dependency, with a decreased viscosity of 17,800 cP being obtained at
37 ◦C ± 2 ◦C rising to 21,800 cP at 25 ◦C ± 2 ◦C. This data therefore suggests that the MH coating is
more likely to migrate freely into the bacteria-seeded agar during testing, as a result of low viscosity at
37 ◦C.
A previous investigation of the antibacterial activity of MH and MGO in a liquid form reported
that higher levels of MGO alone were required to inhibit the growth of P. aeroginosa when compared
with MH where equivalent MGO concentrations were apparent [42]. Secondly, the presence of
hydrogen peroxide in the MH may contribute to the heightened antibacterial effect [42–45].
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Figure 4. FEGSEM of dry TENCEL® fibres (A), synthetic O-coated fibres (B) and MH-coated fibres
(C,D) taken at a magnification of 500 (A–C) 000× ( ). The concentration of MGO on both the
MGO- and MH-coated samples was 0.1 mg c 2. i eter of the uncoated TENCEL fibres ranged
between 10 and 15 µm. The MGO-coated fibres ranged from 10 µm to 25 µm (this is due to the swelling
of the TENCEL fibres after coating).
Comparing the results obtained using both antibacterial methods, the concentration of MGO
required to produce an antibacterial effect was found to be slightly lower (0.0054 mg cm2) when
assessed according to BS EN ISO 20743:2007, compared to concentrations between 0.0170 mg cm2 and
0.1 mg cm2 for E. coli and S. aureus respectively when using BS EN ISO 20645:2004. The lower MGO
concentration achieved using BS EN ISO 20743:2007 may be attributed to the addition of the liquid used
to simulate wound exudate (SCDLP) solution during testing [34]. This would result in the TENCEL®
fibres being exposed to higher moisture content, which could encourage the hydration of the fibres and
facilitate extraction of the MGO. In the case of BS EN ISO 20645:2004 an insufficient moisture content
is available to initiate the diffusion of the MGO from the fibres [38]. It is only when the nonwoven
samples becom increa ly hydrated that the diffusion of MGO into he agar is promoted.
2.2. MIC and MBC of MGO against Common Wound Pathogens
In addition to coatings on nonwov n fabric, Table 6 gives the results of the MIC and MBC of MGO
in liquid form against gram-positive S. aureus, gram-negative P. aeruginosa, and gram-positive E. faecalis.
For P. aeruginosa the MIC against the ATCC strain and patient 1 strain was found to be 512 mg L−1.
Twice the concentration was required (1024 mg L−1) to inhibit the growth of the patient 2 strain.
Upon the subculture of all three isolates, the MBC required to kill the P. aeruginosa ATCC strain was
doubled to 1024 mg L−1, while the two patient strains remained at 512 mg L−1. These concentrations
were the highest among each bacterium species tested, as the MIC for S. aureus ranged from 126 mg L−1
to 256 mg L−1, while E. faecalis did not r ach above 512 mg L−1. It is not surprising that the relatively
high concentrations required to inhibit or kill P. aeroginosa were found, as P. aeruginosa is one of the
most problematic multidrug-resistant gram-negative strains, and is showing increasing resistance to
common antibiotics, including ciprofloxacin [46], amikacin, and imipenem [47]. Previous studies have
reported limited findings on the MBC of MGO against P. aeruginosa. One previous study reported the
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MBC of both MRSA and P. aeruginosa in a planktonic and biofilm state. In the planktonic state, the MBC
for P. aeruginosa was found to range between 600 mg L−1 to 1200 mg L−1, while in the biofilm state the
MBC was found to be much higher, ranging from 1800 mg L−1 to 7600 mg L−1 [48]. The raised MBC
of MGO can be expected in a biofilm state, as the polysaccharide (Psl) in P. aeruginosa biofilms has
been shown to provide a physical barrier against various antibiotics at the beginning stages of biofilm
development [49]. In the current study, the MBC was only tested in the planktonic state and shows a
slightly lower MBC between 512 mg L−1 and 1024 mg L−1 than in the previous study.
The lowest MIC and MBC results were found to be against gram-positive S. aureus, reportedly the
most common bacterium species found in a chronic wound environment [31]. The ATCC strain showed
the lowest MIC of 128 mg L−1, while the two patient strains did not exceed 256 mg L−1 for both the
MIC and MBC. Previous studies have reported a range of MGO concentrations required to inhibit or
kill S. aureus. One study reported a lower MIC of 79.3 mg L−1 (1.1 mM) [20], while another reported
a biocidal effect of MGO in MH, with an MGO concentration of 530 mg L−1 against biofilms [50].
In the same study, the concentration of MGO alone (non-Manuka honey sample) required to achieve a
biocidal effect against biofilms was >1050 mg L−1, which is four times higher than the concentration
reported in the current study (256 mg L−1). However, the current study has only tested the effect of
MGO against S. aureus in the planktonic state, and so a lower concentration is to be expected.
Table 6. Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC)
(mg L−1) of MGO in liquid form against three common wound pathogens. VRE: vancomycin-resistant
Enterococcus faecalis.
Test Organism MIC (mg L−1) MIC (mM) MBC (mg L−1) MBC (mM)
Pseudomonas aeruginosa ATCC27853 512 7.1 1024 14.2
Pseudomonas aeruginosa patient 1 512 7.1 512 7.1
Pseudomonas aeruginosa patient 2 1024 14.2 1024 14.2
Staphylococcus aureus ATCC29213 128 1.8 256 3.6
Staphylococcus aureus patient 1 256 3.6 256 3.6
Staphylococcus aureus patient 2 256 3.6 256 3.6
Enterococcus faecalis ATCC21292 256 3.6 256 3.6
VRE patient 1 512 7.1 512 7.1
VRE patient 2 512 7.1 512 7.1
The MIC and MBC of MGO against E. faecalis, has, to the authors knowledge, not been
previously reported. One study reported the effect of Activon MH dressing against vancomycin-resistant
Enterococcus faecalis (VRE), stating that a 5% (w/v) concentration was needed to initiate an antibacterial
effect against the biofilm. Yet no reference was made throughout the study in relation to MGO.
In the current study, equivalent MIC and MBC were shown to be effective for the ATCC strain at a
concentration of 256 mg L−1 and the two patient strains with a concentration of 512 mg L−1. E. faecalis is
reported to be the second most prevalent bacteria found in a chronic wound environment [33], therefore
it was of importance to discover the required concentration of MGO to provide a bacteriostatic and
bactericidal effect in a planktonic state.
In light of the MIC and MBC concentrations found in this study, it is conceivable that MGO
concentrations covering these ranges are likely found in Manuka dressings currently applied in clinical
situations. Previous studies have only addressed the concentration of Manuka honey in a commercial
dressing in terms of w/v, with no specific reference to MGO content. Therefore, this study along
with the work by Mavrik et al. [20] and Jervis et al. [50], gives an indication of the appropriate MGO
concentrations required to inhibit or kill a broader spectrum of bacterial strains.
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3. Materials and Methods
3.1. Materials
A 40 wt % MGO aqueous solution was purchased from Sigma Aldrich, Haverhill, UK. Manuka
honey 550+ was purchased from Wellbeing, Birmingham, UK and TENCEL® cellulose fibres with a
linear density of 1.7 dtex and length of 10 mm were obtained from Lenzing AG, Lenzing, Austria.
3.2. Preparations of MH and MGO Coating Solutions
A 20% (w/w) and a 60% (w/w) aqueous solution of MH was prepared by dissolving 100 g and 300 g
of Manuka honey (MGO 550+) respectively, in distilled water and made up to 500 g. The concentration
of MGO of the two solutions was calculated as 0.11 mg g−1 and 0.33 mg g−1 respectively. A 40 wt %
MGO solution was diluted with distilled water to obtain equivalent concentrations of MGO.
3.3. Preparation of Coated Nonwoven Dressings
Prior to the manufacture of the nonwoven samples, TENCEL® fibres were opened using a Shirley
fibre blender. Airlaid webs with a basis weight of 120 g m−2 were produced from 100% TENCEL®
fibre using a short fibre airlaying machine in which the fibres are sifted through a static screen aided by
rotating blades. The webs were mechanically bonded by hydroentanglement (water jet entanglement)
using an STL Hydrolace system with a 110–120 µm diameter jet strip and a jet pressure of 50 bar
on one side and 50 bar on the reverse. The hydroentangled webs were washed with warm water
and fabric detergent to remove residual chemical finish on the fibres after hydroentangling. Using a
sample liquor ratio of 1:50, the coatings were applied by immersing samples into the prepared MH
and MGO coating solutions for 10 min. The samples were then passed through a pad mangle at a
pressure of 10 kg cm−2, weighed and left to air dry at room temperature. A coating-free sample was
also prepared and used as a control (NW). The amount of MGO per unit area (mg cm−2) absorbed onto
the coated nonwoven samples was calculated to range between 0.0054 mg cm−2 and 0.0170 mg cm−2,
as indicated in Table 1. Following initial antibacterial testing at these relatively low concentrations,
additional coated nonwoven samples were prepared to provide six new MGO concentrations between
0.1 mg cm−2 and 1.2 mg cm−2. This was achieved by the addition of either MH or MGO to the premade
coated nonwovens. A 7 cm2 sample was placed in a weighing boat and weighed on a microbalance.
The addition of MH or MGO to the nonwoven sample equated to the required weight needed to give
the new range of MGO concentrations between 0.1 mg cm−2 and 1.2 mg cm−2. Prior to addition of the
Manuka honey 550+, the honey was heated in an incubator at 40 ◦C to allow it to soften and enable a
homogeneous distribution over the nonwoven sample. Note that it was not possible to prepare MH
samples at concentrations above 0.2 mg cm−2, as the nonwoven samples could not retain additional
material due to the high density and viscous nature of the honey.
3.4. Characterisation of the Nonwoven Coated Samples
3.4.1. Morphology of the Coated Nonwoven Samples
The coated nonwoven samples were inspected using an FEI Quanta 200F Field Emission Scanning
Electron Microscope (FEGSEM), Hillsboro, USA. Prior to imaging, all samples were cut and mounted
onto 25 mm aluminum stubs and sputter coated with gold in a vacuum of 0.05 torr for 4 min at 20 mA.
A voltage of 15 kV and a vacuum pressure in the order of 10−6 mbar was achieved in the chamber.
Magnifications between ×500 and ×1000 were used in order to record the morphological features of
individual nonwoven coated samples.
3.4.2. Viscosity Measurements of the MH Coatings
A Brookfield LV viscometer (DV–E), purchased from Harlow, UK was used to measure the
viscosity of the MH (MGO 550+) solutions. The solution viscosity of the MH was measured at a
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temperature of 25 ◦C ± 2 ◦C and 37 ◦C ± 2 ◦C to assess temperature dependency. In order for the
chamber and solution to reach the specific temperature required, 16.1 mL of the MH was decanted into
the chamber and conditioned in an S1 500 Orbital Incubator at the required temperature for 24 h prior
to testing. The spindle was also conditioned to the correct temperature. A speed of 6 r min−1 and a
spindle size of 18 were used.
3.5. Antibacterial Evaluation of MH and MGO-Coated Nonwoven Samples
The antibacterial activity of the MH- and MGO-coated nonwoven samples was determined
using two standard methods, BS EN ISO 20743:2007 (Textiles-Determination of antibacterial activity
of antibacterial finished products) [34] and BS EN ISO 20645:2004 (Textile fabrics-Determination
of antibacterial activity, agar diffusion plate test) [38]. The first method simulates the effect of an
antibacterial dressing in contact with contaminated wound exudate [51] and was used to indicate the
antibacterial effect at equivalent MGO concentrations. The second method made an assessment of
the MH- and MGO-coated nonwovens, as well as the NW using a bacteria-seeded agar plate. A brief
description of each method is given below.
3.5.1. BS EN ISO 20743:2007 (Textiles-Determination of Antibacterial Activity of Antibacterial
Finished Products)
Test pieces with a mass of 0.40 g ± 0.05 g were cut into suitable sizes for testing. Six control
specimens and six antibacterial specimens were prepared, based on standard protocols [34]. In this
study bacteria cultures of both S. aureus and K. pneumonia were prepared to concentrations between
1–3 × 105 per 10 mL in 1 in 20 nutrient broth. The test specimens were placed in sterile jars and
inoculated with 0.2 mL of bacterial suspension on several areas of the sample, taking care to prevent
contact of the suspension with the jar surface. Immediately after inoculation, 20 mL of SCDLP medium
(simulated wound exudate) was added to three of the control jars and three of the antibacterial sample
jars. The jars were sealed with caps and shaken in an arc of approximately 30 cm by hand for 30 s.
The number of bacteria recovered from the samples was then determined using a standard serial
dilution and pour plate technique using peptone salt solution as the dilutant and enumeration agar.
The remaining jars were incubated at 37 ◦C for 24 h. After the incubation period, the number of
bacteria that could be recovered was determined using the equation in the standard.
3.5.2. BS EN ISO 20645:2004 (Textile Fabrics-Determination of Antibacterial Activity, Agar Diffusion
Plate Test)
A circular specimen of fabric with a diameter of 25 ± 5 mm was cut from the test sample.
Two specimens of the antibacterial fabric and two control specimens without the addition of
antibacterial treatment were prepared, based on standard protocols [38]. The specimens were stored
between 12 h to 24 h in sterilized petri dishes at room temperature. Separate agar plates were inoculated
with S. aureus and E. coli bacterial species via streaking the plates with an inoculation loop from a
solution containing 1–5 × 108 colony forming units per mL. The test specimen was placed onto the
bacterial inoculated agar surface using a sterilized pair of tweezers until the texture of the specimen
was uniformly imprinted onto the agar. The petri dishes were placed in the incubator for 24 h at
37 ◦C ± 1 ◦C. Immediately after this period the petri dishes were examined for bacterial growth. If any
zone of inhibition was formed around the test specimens, the diameter of the zone was measured using
a pair of calibrated callipers. The microbial zone of inhibition was calculated using the equation in the
standard. Table 7 shows the criteria stipulated in the standard for defining the effect of an antibacterial
treatment [38].
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Table 7. Stipulated criteria for defining the effect of an antibacterial treatment.
Inhibition
Zone (mm) Growth
a Description Assessment
>1 None inhibition zone exceeding 1 mm, no growth b
Good effect1–0 None inhibition zone up to 1 mm, no growth b
0 None no inhibition zone, no growth c
0 Slight no inhibition zone, only some restricted colonies,growth nearly totally suppressed d Limit of efficacy
0 Moderate no inhibition zone, compare to the control growthreduced to half e Insufficient effect
0 Heavy no inhibition zone, compare to the control nogrowth reduction or only slightly reduced growth
a The growth of bacteria in the nutrient medium under the specimen; b The extent of the inhibition shall only partly
be taken into account. A large inhibition zone may indicate certain reserves of active substances or a weak fixation
of a product on the substrate; c The absence of growth, even without inhibition zone, may be regarded as a good
effect, as the formation of such an inhibition zone may have been prevented by a low diffusibility of the active
substance; d “As good as no growth” indicates the limits of efficacy; e Reduced density of bacterial growth means
either the number of colonies or the colony diameter.
3.5.3. Antibacterial Evaluation of MGO Solutions against Common Wound Pathogens
Using a standard laboratory assay [52], the MIC and MBC of MGO was determined against three
common wound pathogens. A 40 wt % MGO solution was diluted to concentrations between 1 mg L−1
to 1026 mg L−1 by diluting a working stock solution in Mueller Hinton broth. These concentrations
were chosen based on similar concentrations reviewed in the current literature [42]. The dilution
series was dispensed across all rows of a 96-well microtitre tray in 50 µL amounts. Three of the most
common bacterial isolates found in wounds, including S. aureus, P. aeruginosa and E. faecalis, were
chosen for the study. Two separate strains were collected from patients following ethical approval,
and an American type culture collection (ATCC) standard of each was also used. The bacteria isolates
were inoculated on to fresh blood (FBA) agar plates and incubated aerobically at 37 ◦C for 18–24 h.
Single colonies of each bacterial isolate were removed from the agar plates and resuspended in 5 mL
Mueller Hinton Broth to a 0.5 MacFarland turbidity equivalent (1 × 108 CFU·mL−1). Starting with the
non-MG-containing growth control, and then working from the lowest to the highest MG-containing
broth, duplicate rows of the 96-well MIC plates were inoculated with 20 µL of each bacterial isolate,
to yield a bacterial concentration of 2 × 106 per well. Inoculation of the MIC plates occurred within
15 min of inoculum preparation, and these were then incubated at 37 ◦C for 18–24 h. The MIC was
defined as the lowest concentration of MGO that completely inhibited the growth of the bacterial
isolates as detected by the unaided eye. In order to determine whether the growth inhibition at any
particular dilution was bactericidal or bacteriostatic, triplicate 20 µL aliquots were inoculated onto
each of three thirds of an FBA agar plate and spread over the surface of the FBA agar third with a
sterile inoculating loop. Inoculated FBA plates were then incubated at 37 ◦C for 18–24 h. The MBC
was defined as the lowest concentration at which there was no visible bacterial growth upon the FBA.
4. Conclusions
This study provides the first comparison of equivalent MGO concentrations per unit area in MH
and MGO that are required to provide an antibacterial effect when applied as a physical coating to
a nonwoven wound dressing fabric. The antibacterial efficiency was investigated using both BS EN
ISO 20743:2007 and BS EN ISO 20645:2004 to determine if synthetic MGO provided a comparable
antibacterial effect to MH. In the first instance, the bacteria-inoculated samples were immersed in 20 mL
of simulated wound exudate fluid, and it was found that an MGO concentration of 0.0054 mg cm−2
for both MH and MGO was sufficient to achieve a 100% reduction in bacteria when tested against
gram-positive S. aureus and gram-negative K. pneumonia.
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Experiments using bacteria-seeded agar plates found that higher concentrations of MGO, between
0.0170 mg cm−2 and 0.1 mg cm−2, were required to produce a good antibacterial effect against E. coli
and S. aureus. In the case of BS EN ISO 20743:2007, hygroscopic TENCEL® fibres are hydrated due
to the addition of 20 mL of SCDLP, which is likely to encourage MGO diffusion, as compared to BS
EN ISO 20645:2004, where samples are only incubated with agar and limited moisture is available to
facilitate the diffusion mechanism.
The MH-coated nonwovens produced zones of inhibition at relatively low MGO concentrations of
between 0.1 mg cm−2 and 0.2 mg cm−2, as compared with MGO-only coated nonwovens. Clear zones
of inhibition were not apparent until an MGO concentration threshold was reached, at 0.4 mg cm−2 for
E. coli and 0.8 mg cm−2 for S. aureus. This difference was attributed to the incubation of the samples at
37 ◦C during testing, where the MH coating is likely to soften promoting more rapid diffusion into the
bacteria-seeded agar from the fibres, as compared to the less viscous MGO coating, more of which is
retained by the TENCEL® fibres. Manuka honey also contains hydrogen peroxide, which is likely to
contribute to the heightened antibacterial effect when compared with MGO.
Limited research has previously been reported regarding the MIC and MBC of MGO. In this
study, the MIC and MBC against P. aeuroginosa was found be lower than that previously reported in
the literature when in a planktonic state. The MIC and MBC for S. aureus was found to be between the
two previously reported results of 79.3 mg L−1 [20] and >1050 mg L−1 [48,50] where the >1050 mg L−1
value relates to the antimicrobial effect of MGO against biofilms. The MIC and MBC of MGO against
E. facaelis is reported for the first time in the present study.
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